Related Experiment Video
Updated: Apr 19, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Current status of castration resistant prostate cancer basic research]
Abstract:
Recently, novel anti-androgen and CYP-17 inhibitor have been introduced in clinical practice and significance of androgen mediated pathway is re-acknowledged in basic research of castration resistant prostate cancer (CRPC). Generations of AR splicing variant and/or AR mutation, which result in ligand independent activation of AR, are still primary mechanism of acquiring castration resistance in addition to classical AR amplification. Chromosomal rearrangement through FOXA emerged as novel AR regulating mechanism. TMPRSS2-ERG gene fusion is one of the most prevalent signatures in CRPC. Regulation through non-coding miRNA also play critical role in AR mediated oncogenic pathways. Here we describe the classical and recent topics in basic research of CRPC.
Insights
Novel therapies highlight the importance of androgen pathways in castration-resistant prostate cancer (CRPC). Research explores AR alterations, gene fusions like TMPRSS2-ERG, and miRNA regulation in CRPC progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Recent advancements in anti-androgen therapies and CYP-17 inhibitors have renewed focus on androgen signaling in castration-resistant prostate cancer (CRPC).
- Understanding the molecular mechanisms driving CRPC is crucial for developing effective treatments.
Purpose:
- To review classical and emerging topics in the basic research of castration-resistant prostate cancer.
- To highlight key molecular alterations and regulatory pathways involved in CRPC development.
Summary:
- Castration resistance in prostate cancer is driven by androgen receptor (AR) amplification, mutations, and splicing variants leading to ligand-independent activation.
- Novel AR regulation mechanisms include chromosomal rearrangements involving FOXA and the prevalent TMPRSS2-ERG gene fusion.
- Non-coding microRNAs (miRNAs) also play a significant role in AR-mediated oncogenic pathways in CRPC.
Impact:
- This review provides a comprehensive overview of current research frontiers in CRPC.
- It aids researchers in understanding the complex molecular landscape of CRPC.
- Informs the development of targeted therapies for advanced prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers